These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 34577877)

  • 1. Relation between Alpha-Synuclein and Core CSF Biomarkers of Alzheimer's Disease.
    Monge-García V; García-Ayllón MS; Sáez-Valero J; Sánchez-Payá J; Navarrete-Rueda F; Manzanares-Robles J; Gasparini-Berenguer R; Romero-Lorenzo R; Cortés-Gómez MA; Monge-Argilés JA
    Medicina (Kaunas); 2021 Sep; 57(9):. PubMed ID: 34577877
    [No Abstract]   [Full Text] [Related]  

  • 2. Measurement of CSF α-synuclein improves early differential diagnosis of mild cognitive impairment due to Alzheimer's disease.
    García-Ayllón MS; Monge-Argilés JA; Monge-García V; Navarrete F; Cortés-Gómez MA; Sánchez-Payá J; Manzanares J; Gasparini-Berenguer R; Leiva-Santana C; Sáez-Valero J
    J Neurochem; 2019 Jul; 150(2):218-230. PubMed ID: 31077373
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differential role of CSF fatty acid binding protein 3, α-synuclein, and Alzheimer's disease core biomarkers in Lewy body disorders and Alzheimer's dementia.
    Chiasserini D; Biscetti L; Eusebi P; Salvadori N; Frattini G; Simoni S; De Roeck N; Tambasco N; Stoops E; Vanderstichele H; Engelborghs S; Mollenhauer B; Calabresi P; Parnetti L
    Alzheimers Res Ther; 2017 Jul; 9(1):52. PubMed ID: 28750675
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CSF Synaptic Biomarkers in AT(N)-Based Subgroups of Lewy Body Disease.
    Barba L; Abu-Rumeileh S; Halbgebauer S; Bellomo G; Paolini Paoletti F; Gaetani L; Oeckl P; Steinacker P; Massa F; Parnetti L; Otto M
    Neurology; 2023 Jul; 101(1):e50-e62. PubMed ID: 37188538
    [TBL] [Abstract][Full Text] [Related]  

  • 5. α-Synuclein Heteromers in Red Blood Cells of Alzheimer's Disease and Lewy Body Dementia Patients.
    Daniele S; Baldacci F; Piccarducci R; Palermo G; Giampietri L; Manca ML; Pietrobono D; Frosini D; Nicoletti V; Tognoni G; Giorgi FS; Lo Gerfo A; Petrozzi L; Cavallini C; Franzoni F; Ceravolo R; Siciliano G; Trincavelli ML; Martini C; Bonuccelli U
    J Alzheimers Dis; 2021; 80(2):885-893. PubMed ID: 33579836
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cerebrospinal fluid α-synuclein and Lewy body-like symptoms in normal controls, mild cognitive impairment, and Alzheimer's disease.
    Mackin RS; Insel P; Zhang J; Mohlenhoff B; Galasko D; Weiner M; Mattsson N
    J Alzheimers Dis; 2015; 43(3):1007-16. PubMed ID: 25125463
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cerebrospinal fluid β-synuclein as a synaptic biomarker for preclinical Alzheimer's disease.
    Barba L; Abu Rumeileh S; Bellomo G; Paolini Paoletti F; Halbgebauer S; Oeckl P; Steinacker P; Massa F; Gaetani L; Parnetti L; Otto M
    J Neurol Neurosurg Psychiatry; 2023 Jan; 94(1):83-86. PubMed ID: 35944974
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The value of cerebrospinal fluid α-synuclein and the tau/α-synuclein ratio for diagnosis of neurodegenerative disorders with Lewy pathology.
    Førland MG; Tysnes OB; Aarsland D; Maple-Grødem J; Pedersen KF; Alves G; Lange J
    Eur J Neurol; 2020 Jan; 27(1):43-50. PubMed ID: 31293044
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differential diagnostic value of total alpha-synuclein assay in the cerebrospinal fluid between Alzheimer's disease and dementia with Lewy bodies from the prodromal stage.
    Bousiges O; Philippi N; Lavaux T; Perret-Liaudet A; Lachmann I; Schaeffer-Agalède C; Anthony P; Botzung A; Rauch L; Jung B; de Sousa PL; Demuynck C; Martin-Hunyadi C; Cretin B; Blanc F
    Alzheimers Res Ther; 2020 Sep; 12(1):120. PubMed ID: 32993772
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cerebrospinal fluid α-synuclein contributes to the differential diagnosis of Alzheimer's disease.
    Shi M; Tang L; Toledo JB; Ginghina C; Wang H; Aro P; Jensen PH; Weintraub D; Chen-Plotkin AS; Irwin DJ; Grossman M; McCluskey L; Elman LB; Wolk DA; Lee EB; Shaw LM; Trojanowski JQ; Zhang J
    Alzheimers Dement; 2018 Aug; 14(8):1052-1062. PubMed ID: 29604263
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CSF total tau/α-synuclein ratio improved the diagnostic performance for Alzheimer's disease as an indicator of tau phosphorylation.
    Shim KH; Kang MJ; Suh JW; Pyun JM; Ryoo N; Park YH; Youn YC; Jang JW; Jeong JH; Park KW; Choi SH; Suk K; Lee HW; Ko PW; Lee CN; Lim TS; An SSA; Kim S;
    Alzheimers Res Ther; 2020 Jul; 12(1):83. PubMed ID: 32660565
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neuropsychiatric symptoms and α-Synuclein profile of patients with Parkinson's disease dementia, dementia with Lewy bodies and Alzheimer's disease.
    Bougea A; Stefanis L; Paraskevas GP; Emmanouilidou E; Efthymiopoulou E; Vekrelis K; Kapaki E
    J Neurol; 2018 Oct; 265(10):2295-2301. PubMed ID: 30083953
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Natural speech markers of Alzheimer's disease co-pathology in Lewy body dementias.
    Shellikeri S; Cho S; Cousins KAQ; Liberman M; Howard E; Balganorth Y; Weintraub D; Spindler M; Deik A; Lee EB; Trojanowski JQ; Irwin D; Wolk D; Grossman M; Nevler N
    Parkinsonism Relat Disord; 2022 Sep; 102():94-100. PubMed ID: 35985146
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Alpha-synuclein: a pathological factor with Aβ and tau and biomarker in Alzheimer's disease.
    Shim KH; Kang MJ; Youn YC; An SSA; Kim S
    Alzheimers Res Ther; 2022 Dec; 14(1):201. PubMed ID: 36587215
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The diagnostic value of CSF α-synuclein in the differential diagnosis of dementia with Lewy bodies vs. normal subjects and patients with Alzheimer's disease.
    Kapaki E; Paraskevas GP; Emmanouilidou E; Vekrellis K
    PLoS One; 2013; 8(11):e81654. PubMed ID: 24282614
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diagnostic Value of the CSF α-Synuclein Real-Time Quaking-Induced Conversion Assay at the Prodromal MCI Stage of Dementia With Lewy Bodies.
    Rossi M; Baiardi S; Teunissen CE; Quadalti C; van de Beek M; Mammana A; Stanzani-Maserati M; Van der Flier WM; Sambati L; Zenesini C; Caughey B; Capellari S; Lemstra AW; Parchi P
    Neurology; 2021 Aug; 97(9):e930-e940. PubMed ID: 34210822
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High discriminatory ability of peripheral and CFSF biomarkers in Lewy body diseases.
    Bougea A; Stefanis L; Emmanouilidou E; Vekrelis K; Kapaki E
    J Neural Transm (Vienna); 2020 Mar; 127(3):311-322. PubMed ID: 31912280
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CSF levels of the neuronal injury biomarker visinin-like protein-1 in Alzheimer's disease and dementia with Lewy bodies.
    Luo X; Hou L; Shi H; Zhong X; Zhang Y; Zheng D; Tan Y; Hu G; Mu N; Chan J; Chen X; Fang Y; Wu F; He H; Ning Y
    J Neurochem; 2013 Dec; 127(5):681-90. PubMed ID: 23800322
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Amyloid-β and α-synuclein cerebrospinal fluid biomarkers and cognition in early Parkinson's disease.
    Stav AL; Aarsland D; Johansen KK; Hessen E; Auning E; Fladby T
    Parkinsonism Relat Disord; 2015 Jul; 21(7):758-64. PubMed ID: 25971633
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CSF α-synuclein does not discriminate dementia with Lewy bodies from Alzheimer's disease.
    Reesink FE; Lemstra AW; van Dijk KD; Berendse HW; van de Berg WD; Klein M; Blankenstein MA; Scheltens P; Verbeek MM; van der Flier WM
    J Alzheimers Dis; 2010; 22(1):87-95. PubMed ID: 20847452
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.